Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.71 |
| ▸ | MPO | P05164 | 9/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30579356 | 1.00 | GPR84 (0.71) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| Hydrochloric Acid SCHEMBL7819150 | 0.98 | GPR84 (0.69) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL5238057 | 0.90 | GPR84 (0.67) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL20258550 | 0.85 | HTR2A (0.58) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| Hydrochloric Acid SCHEMBL21546041 | 0.83 | HTR2A (0.56) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| Hydrochloric Acid SCHEMBL21546049 | 0.81 | MPO (0.55) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL5791787 | 0.81 | GPR84 (0.65) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL8202576 | 0.81 | HTR2A (0.61) | GPR84MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL30483767 | 0.80 | GPR84 (0.63) | GPR84MPOSLC6A4HTR2AHTR1A | |
| SCHEMBL4506788 | 0.80 | GPR84 (0.63) | GPR84MPOSLC6A4HTR2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4526426-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | Danmarks Tekniske Universitet (DK) | 2025-03-26 | — | — | EP | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2023222879-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-23 | — | — | WO | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | GPR84 100/4885MPO 1679/4885SLC6A4 959/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | GPR84 100/4885MPO 1679/4885SLC6A4 959/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | GPR84 125/4885MPO 4217/4885SLC6A4 22/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | GPR84 125/4885MPO 4217/4885SLC6A4 22/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | GPR84 100/4885MPO 1679/4885SLC6A4 959/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | GPR84 125/4885MPO 4217/4885SLC6A4 22/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | GPR84 3005/4885MPO 4073/4885SLC6A4 1812/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | GPR84 100/4885MPO 1679/4885SLC6A4 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.